Extracellular vesicles in ovarian cancer: Applications to tumor biology, immunotherapy and biomarker discovery

Expert Review of Proteomics

Volumn 13, Issue 4, 2016, Pages 395-409

  Nawaz, Muhammad ^a,b   Fatima, Farah ^a,b   Nazarenko, Irina ^c   Ekström, Karin ^b,d   Murtaza, Iram ^e   Anees, Mariam ^e   Sultan, Aneesa ^e   Neder, Luciano ^a   Camussi, Giovanni ^f   Valadi, Hadi ^b   Squire, Jeremy A ^a   Kislinger, Thomas ^g  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY OF FREIBURG   (Germany)

^d BIOMATCELL VINN Excellence Center of Biomaterials and Cell Therapy   (Sweden)

^e QUAID I AZAM UNIVERSITY   (Pakistan)

^f UNIVERSITY OF TURIN   (Italy)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

biomarkers; exosomes; Extracellular vesicles; glycoproteins; immunotherapy; matrix metalloproteinase; microRNAs; ovarian cancer

Indexed keywords

BIOLOGICAL MARKER; CANCER VACCINE; MICRORNA; TUMOR ANTIGEN; TUMOR MARKER;

ANTIGEN PRESENTING CELL; BIOGENESIS; CANCER CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CELL MATURATION; EFFECTOR CELL; EXOSOME; FEMALE; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSURVEILLANCE; NEXT GENERATION SEQUENCING; OVARY CANCER; REVIEW; SURVIVAL RATE; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; ANIMAL; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; OVARIAN NEOPLASMS; PROCEDURES; PROTEOMICS;

ANIMALS; BIOMARKERS, TUMOR; EXTRACELLULAR VESICLES; FEMALE; HUMANS; IMMUNOTHERAPY; MICRORNAS; OVARIAN NEOPLASMS; PROTEOMICS;

EID: 84962430694     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2016.1165613     Document Type: Review

References (175)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63 (1): 11-30
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65 (1): 5-29
3. McCluggage WG. Morphological subtypes of ovarian carcinoma: A review with emphasis on new developments and pathogenesis. Pathology. 2011; 43 (5): 420-432
4. Kanchi KL, Johnson KJ, Lu C, et al. Integrated analysis of germline and somatic variants in ovarian cancer. Nat Commun. 2014; 5: 3156
5. Yang D, Sun Y, Hu L, et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 2013; 23 (2): 186-199
6. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474 (7353): 609-615
7. Sturgeon CM, Duffy MJ, Walker G. The National Institute for Health and Clinical Excellence (NICE) guidelines for early detection of ovarian cancer: The pivotal role of the clinical laboratory. Ann Clin Biochem. 2011; 48 (Pt 4): 295-299
8. Berns EM, Bowtell DD. The changing view of high-grade serous ovarian cancer. Cancer Res. 2012; 72 (11): 2701-2704
9. Lutz AM, Willmann JK, Drescher CW, et al. Early diagnosis of ovarian carcinoma: Is a solution in sight? Radiology. 2011; 259 (2): 329-345
10. Weberpals JI, Koti M, Squire JA. Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer. Cancer Genet. 2011; 204 (10): 525-535
11. Seoung JPY, Rhim C, Kim S. Current possible drug therapies for ovarian cancer. J Cancer Ther. 2014; 5 (13): 1203-1214
12. Pinato DJ, Graham J, Gabra H, et al. Evolving concepts in the management of drug resistant ovarian cancer: Dose dense chemotherapy and the reversal of clinical platinum resistance. Cancer Treat Rev. 2013; 39 (2): 153-160
13. Barrena Medel NI, Wright JD, Herzog TJ. Targeted therapies in epithelial ovarian cancer. J Oncol. 2010; 2010: 314326
14. Nawaz M, Camussi G, Valadi H, et al. The emerging role of extracellular vesicles as biomarkers for urogenital cancers. Nat Rev Urol. 2014; 11 (12): 688-701
15. Raposo G, Stoorvogel W. Extracellular vesicles: Exosomes, microvesicles, and friends. J Cell Biol. 2013; 200 (4): 373-383
16. Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 9 (6): 654-659
17. Skog J, Wurdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10 (12): 1470-1476
18. Al-Nedawi K, Meehan B, Micallef J, et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol. 2008; 10 (5): 619-624
19. Melo SA, Sugimoto H, OConnell JT, et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell. 2014; 26 (5): 707-721
20. Kim DK, Lee J, Kim SR, et al. EVpedia: A community web portal for extracellular vesicles research. Bioinformatics. 2015; 31 (6): 933-939
21. Hoshino A, Costa-Silva B, Shen TL, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015; 527 (7578): 329-335
22. Gomes J, Gomes-Alves P, Carvalho SB, et al. Extracellular vesicles from ovarian carcinoma cells display specific glycosignatures. Biomolecules. 2015; 5 (3): 1741-1761
23. Costa-Silva B, Aiello NM, Ocean AJ, et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol. 2015; 17 (6): 816-826
24. An T, Qin S, Xu Y, et al. Exosomes serve as tumour markers for personalized diagnostics owing to their important role in cancer metastasis. J Extracell Vesicles. 2015; 4: 27522
25. Lin J, Li J, Huang B, et al. Exosomes: Novel biomarkers for clinical diagnosis. ScientificWorldJournal. 2015; 2015: 657086
26. Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014; 30: 255-289
27. Yanez-Mo M, Siljander PR, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015; 4: 27066
28. Nawaz M, Fatima F, Vallabhaneni KC, et al. Extracellular vesicles: Evolving factors in stem cell biology. Stem Cells Int. 2016; 2016: 1073140
29. Fatima F, Nawaz M. Stem cell-derived exosomes: Roles in stromal remodeling, tumor progression, and cancer immunotherapy. Chin J Cancer. 2015; 34 (3): 46
30. Peinado H, Aleckovic M, Lavotshkin S, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012; 18 (6): 883-891
31. Al-Nedawi K, Meehan B, Kerbel RS, et al. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci U S A. 2009; 106 (10): 3794-3799
32. Robbins PD, Morelli AE. Regulation of immune responses by extracellular vesicles. Nat Rev Immunol. 2014; 14 (3): 195-208
33. Gobbo J, Marcion G, Cordonnier M, et al. Restoring anticancer immune response by targeting tumor-derived exosomes with a HSP70 peptide aptamer. J Natl Cancer Inst. 2016; 108: 3
34. Mitchell PJ, Welton J, Staffurth J, et al. Can urinary exosomes act as treatment response markers in prostate cancer? J Transl Med. 2009; 7: 4
35. Ge Q, Zhou Y, Lu J, et al. miRNA in plasma exosome is stable under different storage conditions. Molecules. 2014; 19 (2): 1568-1575
36. Kowal J, Tkach M, Thery C. Biogenesis and secretion of exosomes. Curr Opin Cell Biol. 2014; 29: 116-125
37. Akers JC, Gonda D, Kim R, et al. Biogenesis of extracellular vesicles (EV): Exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J Neurooncol. 2013; 113 (1): 1-11
38. Witwer KW, Buzas EI, Bemis LT, et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles. 2013; 2:20360
39. Dembo AJ, Davy M, Stenwig AE, et al. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol. 1990; 75 (2): 263-273
40. Puls LE, Duniho T, Hunter JE, et al. The prognostic implication of ascites in advanced-stage ovarian cancer. Gynecol Oncol. 1996; 61 (1): 109-112
41. Enriquez VA, Cleys ER, Da Silveira JC, et al. High LIN28A expressing ovarian cancer cells secrete exosomes that induce invasion and migration in HEK293 cells. Biomed Res Int. 2015; 2015: 701390
42. Vaksman O, Trope C, Davidson B, et al. Exosome-derived miRNAs and ovarian carcinoma progression. Carcinogenesis. 2014;35(9):2131-2120
43. Graves LE, Ariztia EV, Navari JR, et al. Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. Cancer Res. 2004; 64 (19): 7045-7049
44. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008; 110 (1): 13-21
45. Kobayashi M, Salomon C, Tapia J, et al. Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 miRNA and miR-200. J Transl Med. 2014; 12: 4
46. Sinha A, Ignatchenko V, Ignatchenko A, et al. In-depth proteomic analyses of ovarian cancer cell line exosomes reveals differential enrichment of functional categories compared to the NCI 60 proteome. Biochem Biophys Res Commun. 2014; 445 (4): 694-701
47. Gercel-Taylor C, Atay S, Tullis RH, et al. Nanoparticle analysis of circulating cell-derived vesicles in ovarian cancer patients. Anal Biochem. 2012; 428 (1): 44-53
48. An HJ, Miyamoto S, Lancaster KS, et al. Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer. J Proteome Res. 2006; 5 (7): 1626-1635
49. de la Fuente A, Alonso-Alconada L, Costa C, et al. M-Trap: Exosome-based capture of tumor cells as a new technology in peritoneal metastasis. J Natl Cancer Inst. 2015; 107 (9). pii: Djv184. doi: 10.1093/jnci/djv184
50. Pospichalova V, Svoboda J, Dave Z, et al. Simplified protocol for flow cytometry analysis of fluorescently labeled exosomes and microvesicles using dedicated flow cytometer. J Extracell Vesicles. 2015; 4: 25530
51. Zhao Z, Yang Y, Zeng Y, et al. A microfluidic ExoSearch chip for multiplexed exosome detection towards blood-based ovarian cancer diagnosis. Lab Chip. 2016;16(3):489-496
52. Zhang W, Peng P, Kuang Y, et al. Characterization of exosomes derived from ovarian cancer cells and normal ovarian epithelial cells by nanoparticle tracking analysis. Tumour Biol. 2015. doi: 10.1007/s13277-015-4105-8
53. Dolo V, DAscenzo S, Violini S, et al. Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro. Clin Exp Metastasis. 1999; 17 (2): 131-140
54. Ginestra A, La Placa MD, Saladino F, et al. The amount and proteolytic content of vesicles shed by human cancer cell lines correlates with their in vitro invasiveness. Anticancer Res. 1998; 18 (5a): 3433-3437
55. Taylor DD, Lyons KS, Gercel-Taylor C. Shed membrane fragment-associated markers for endometrial and ovarian cancers. Gynecol Oncol. 2002; 84 (3): 443-448
56. Hakulinen J, Junnikkala S, Sorsa T, et al. Complement inhibitor membrane cofactor protein (MCP; CD46) is constitutively shed from cancer cell membranes in vesicles and converted by a metalloproteinase to a functionally active soluble form. Eur J Immunol. 2004; 34 (9): 2620-2629
57. Runz S, Keller S, Rupp C, et al. Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. Gynecol Oncol. 2007; 107 (3): 563-571
58. Vlodavsky I, Elkin M, Abboud-Jarrous G, et al. Heparanase: One molecule with multiple functions in cancer progression. Connect Tissue Res. 2008; 49 (3): 207-210
59. Keller S, Konig AK, Marme F, et al. Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes. Cancer Lett. 2009; 278 (1): 73-81
60. Rupp AK, Rupp C, Keller S, et al. Loss of EpCAM expression in breast cancer derived serum exosomes: Role of proteolytic cleavage. Gynecol Oncol. 2011; 122 (2): 437-446
61. Liang B, Peng P, Chen S, et al. Characterization and proteomic analysis of ovarian cancer-derived exosomes. J Proteomics. 2013; 80c: 171-182
62. Clancy JW, Sedgwick A, Rosse C, et al. Regulated delivery of molecular cargo to invasive tumour-derived microvesicles. Nat Commun. 2015; 6: 6919
63. Gutwein P, Mechtersheimer S, Riedle S, et al. ADAM10-mediated cleavage of L1 adhesion molecule at the cell surface and in released membrane vesicles. FASEB J. 2003; 17 (2): 292-294
64. Gutwein P, Stoeck A, Riedle S, et al. Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells. Clin Cancer Res. 2005; 11 (7): 2492-2501
65. Fogel M, Gutwein P, Mechtersheimer S, et al. L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet. 2003; 362 (9387): 869-875
66. Stoeck A, Keller S, Riedle S, et al. A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. Biochem J. 2006; 393 (Pt 3): 609-618
67. Baumann P, Cremers N, Kroese F, et al. CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res. 2005; 65 (23): 10783-10793
68. Kristiansen G, Denkert C, Schluns K, et al. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol. 2002; 161 (4): 1215-1221
69. Kristiansen G, Sammar M, Altevogt P. Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol. 2004; 35 (3): 255-262
70. Choi YL, Kim SH, Shin YK, et al. Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors. Gynecol Oncol. 2005; 97 (2): 379-386
71. Li J, Sherman-Baust CA, Tsai-Turton M, et al. Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. BMC Cancer. 2009; 9: 244
72. Konecny GE, Agarwal R, Keeney GA, et al. Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer. Gynecol Oncol. 2008; 109 (2): 263-269
73. Choi YL, Kim J, Kwon MJ, et al. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation. Histol Histopathol. 2007; 22 (11): 1185-1195
74. Kleinberg L, Holth A, Trope CG, et al. Claudin upregulation in ovarian carcinoma effusions is associated with poor survival. Hum Pathol. 2008; 39 (5): 747-757
75. Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015; 348 (6230): 74-80
76. Harris AL. Hypoxia -A key regulatory factor in tumour growth. Nat Rev Cancer. 2002; 2 (1): 38-47
77. Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: Drivers of tumour metastasis. Nat Rev Cancer. 2014; 14 (6): 430-439
78. Parolini I, Federici C, Raggi C, et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem. 2009; 284 (49): 34211-34222
79. Luga V, Zhang L, Viloria-Petit AM, et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell. 2012; 151 (7): 1542-1556
80. Shimoda M, Principe S, Jackson HW, et al. Loss of the Timp gene family is sufficient for the acquisition of the CAF-like cell state. Nat Cell Biol. 2014; 16 (9): 889-901
81. Lis R, Touboul C, Raynaud CM, et al. Mesenchymal cell interaction with ovarian cancer cells triggers pro-metastatic properties. Plos One. 2012; 7 (5): E38340
82. Cho JA, Park H, Lim EH, et al. Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts. Gynecol Oncol. 2011; 123 (2): 379-386
83. Yang Y, Bucan V, Baehre H, et al. Acquisition of new tumor cell properties by MSC-derived exosomes. Int J Oncol. 2015; 47 (1): 244-252
84. Yang Y, Otte A, Hass R. Human mesenchymal stroma/stem cells exchange membrane proteins and alter functionality during interaction with different tumor cell lines. Stem Cells Dev. 2015; 24 (10): 1205-1222
85. Iero M, Valenti R, Huber V, et al. Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ. 2008; 15 (1): 80-88
86. Rak J. Microparticles in cancer. Semin Thromb Hemost. 2010; 36 (08): 888-906
87. Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA: Journal Am Med Assoc. 2002; 287 (13): 1671-1679
88. Grange C, Tapparo M, Collino F, et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 2011; 71 (15): 5346-5356
89. Yi H, Ye J, Yang XM, et al. High-grade ovarian cancer secreting effective exosomes in tumor angiogenesis. Int J Clin Exp Pathol. 2015; 8 (5): 5062-5070
90. Dolo V, DAscenzo S, Giusti I, et al. Shedding of membrane vesicles by tumor and endothelial cells. Ital J Anat Embryol. 2005; 110 (2 Suppl 1): 127-133
91. Taraboletti G, DAscenzo S, Giusti I, et al. Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH. Neoplasia. 2006; 8 (2): 96-103
92. Lee TH, DAsti E, Magnus N, et al. Microvesicles as mediators of intercellular communication in cancer -The emerging science of cellular debris. Semin Immunopathol. 2011; 33 (5): 455-467
93. Millimaggi D, Mari M, DAscenzo S, et al. Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia. 2007; 9 (4): 349-357
94. Yi H, Zheng X, Song J, et al. Exosomes mediated pentose phosphate pathway in ovarian cancer metastasis: A proteomics analysis. Int J Clin Exp Pathol. 2015; 8 (12): 15719-15728
95. Safaei R, Larson BJ, Cheng TC, et al. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther. 2005; 4 (10): 1595-1604
96. Yin J, Yan X, Yao X, et al. Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients. J Cell Mol Med. 2012; 16 (2): 337-348
97. Pink RC, Samuel P, Massa D, et al. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells. Gynecol Oncol. 2015; 137 (1): 143-151
98. Weiner-Gorzel K, Dempsey E, Milewska M, et al. Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells. Cancer Med. 2015; 4 (5): 745-758
99. Zhang FF, Zhu YF, Zhao QN, et al. Microvesicles mediate transfer of P-glycoprotein to paclitaxel-sensitive A2780 human ovarian cancer cells, conferring paclitaxel-resistance. Eur J Pharmacol. 2014; 738: 83-90
100. Liu C, Yu S, Zinn K, et al. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol. 2006; 176 (3): 1375-1385
101. Clayton A, Mitchell JP, Court J, et al. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res. 2007; 67 (15): 7458-7466
102. Yu S, Liu C, Su K, et al. Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol. 2007; 178 (11): 6867-6875
103. Valenti R, Huber V, Iero M, et al. Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res. 2007; 67 (7): 2912-2915
104. Taylor DD, Gercel-Taylor C, Lyons KS, et al. T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer Res. 2003; 9 (14): 5113-5119
105. Andreola G, Rivoltini L, Castelli C, et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med. 2002; 195 (10): 1303-1316
106. Meng Y, Kang S, Fishman DA. Lysophosphatidic acid stimulates fas ligand microvesicle release from ovarian cancer cells. Cancer Immunol Immunother. 2005; 54 (8): 807-814
107. Peng P, Yan Y, Keng S. Exosomes in the ascites of ovarian cancer patients: Origin and effects on anti-tumor immunity. Oncol Rep. 2011; 25 (3): 749-762
108. Abrahams VM, Straszewski SL, Kamsteeg M, et al. Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res. 2003; 63 (17): 5573-5581
109. Taylor DD, Gercel-Taylor C. Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer. 2005; 92 (2): 305-311
110. Rabinowich H, Banks M, Reichert TE, et al. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res. 1996; 2 (8): 1263-1274
111. Blanchard N, Lankar D, Faure F, et al. TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/ζ Complex. J Immunol. 2002; 168 (7): 3235-3241
112. Kelleher RJ, Balu-Iyer S, Loyall JL, et al. Extracellular vesicles present in human ovarian tumor microenvironments induce a phosphatidylserine dependent arrest in the T cell signaling cascade. Cancer Immunol Res. 2015;3(11):1269-1278
113. Koti M, Siu A, Clement I, et al. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer. Br J Cancer. 2015; 112 (7): 1215-1222
114. Bretz NP, Ridinger J, Rupp AK, et al. Body fluid exosomes promote secretion of inflammatory cytokines in monocytic cells via Toll-like receptor signaling. J Biol Chem. 2013; 288 (51): 36691-36702
115. Atay S, Gercel-Taylor C, Taylor DD. Human trophoblast-derived exosomal fibronectin induces pro-inflammatory IL-1beta production by macrophages. Am J Reprod Immunol. 2011; 66 (4): 259-269
116. Raposo G, Nijman H, Stoorvogel W, et al. B lymphocytes secrete antigen-presenting vesicles. J Exp Med. 1996; 183 (3): 1161-1172
117. Wubbolts R, Leckie RS, Veenhuizen PT, et al. Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation. J Biol Chem. 2003; 278 (13): 10963-10972
118. Zitvogel L, Regnault A, Lozier A, et al. Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes. Nat Med. 1998; 4 (5): 594-600
119. Segura E, Amigorena S, Thery C. Mature dendritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responses. Blood Cells Mol Dis. 2005; 35 (2): 89-93
120. Wolfers J, Lozier A, Raposo G, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med. 2001; 7 (3): 297-303
121. Andre F, Schartz NE, Movassagh M, et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet. 2002; 360 (9329): 295-305
122. Li QL, Bu N, Yu YC, et al. Exvivo experiments of human ovarian cancer ascites-derived exosomes presented by dendritic cells derived from umbilical cord blood for immunotherapy treatment. Clin Medicine Oncol. 2008; 2: 461-467
123. Rughetti A, Rahimi H, Belleudi F, et al. Microvesicle cargo of tumor-associated MUC1 to dendritic cells allows cross-presentation and specific carbohydrate processing. Cancer Immunol Res. 2014; 2 (2): 177-186
124. Taylor DD, Gercel-Taylor C, Parker LP. Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol. 2009; 115 (1): 112-120
125. Labani-Motlagh A, Israelsson P, Ottander U, et al. Differential expression of ligands for NKG2D and DNAM-1 receptors by epithelial ovarian cancer-derived exosomes and its influence on NK cell cytotoxicity. Tumour Biol. 2015. doi: 10.1007/s13277-015-4313-2
126. Adams M, Navabi H, Croston D, et al. The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer. Vaccine. 2005; 23 (17-18): 2374-2378
127. Ulevitch RJ. Therapeutics targeting the innate immune system. Nat Rev Immunol. 2004; 4 (7): 512-520
128. Schneeberger A, Wagner C, Zemann A, et al. CpG motifs are efficient adjuvants for DNA cancer vaccines. J Invest Dermatol. 2004; 123 (2): 371-379
129. Gelman AE, Zhang J, Choi Y, et al. Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol. 2004; 172 (10): 6065-6073
130. Navabi H, Croston D, Hobot J, et al. Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial. Blood Cells Mol Dis. 2005; 35 (2): 149-152
131. Szajnik M, Derbis M, Lach M, et al. Exosomes in plasma of patients with ovarian carcinoma: Potential biomarkers of tumor progression and response to therapy. Gynecol Obstet (Sunnyvale). 2013; Suppl 4: 3
132. Chaput N, Schartz NE, Andre F, et al. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol. 2004; 172 (4): 2137-2146
133. Schlienger K, Chu CS, Woo EY, et al. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res. 2003; 9 (4): 1517-1527
134. Morse MA, Garst J, Osada T, et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med. 2005; 3 (1): 9
135. Altieri SL, Khan ANH, Tomasi TB. Exosomes from plasmacytoma cells as a tumor vaccine. J Immunotherapy. 2004; 27 (4): 282-288
136. American College of Obstetricians and Gynecologists. PROLOG gynecology and surgery 6th ed. Washington, DC: American College of Obstetricians and Gynecologists; 2009
137. Montagnana M, Danese E, Giudici S, et al. HE4 in ovarian cancer: From discovery to clinical application. Adv Clin Chem. 2011; 55: 1-20
138. Ueland FR, Desimone CP, Seamon LG, et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol. 2011; 117 (6): 1289-1297
139. Kozak KR, Su F, Whitelegge JP, et al. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics. 2005; 5 (17): 4589-4596
140. Sarojini S, Tamir A, Lim H, et al. Early detection biomarkers for ovarian cancer. J Oncol. 2012; 2012: 709049
141. Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009; 112 (1): 40-46
142. Moore RG, Miller MC, Disilvestro P, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol. 2011; 118 (2 Pt 1): 280-288
143. Giusti I, DAscenzo S, Dolo V. Microvesicles as potential ovarian cancer biomarkers. Biomed Res Int. 2013; 2013: 703048
144. Im H, Shao H, Park YI, et al. Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor. Nat Biotechnol. 2014; 32 (5): 490-495
145. Went PT, Lugli A, Meier S, et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol. 2004; 35 (1): 122-128
146. Carbotti G, Orengo AM, Mezzanzanica D, et al. Activated leukocyte cell adhesion molecule soluble form: A potential biomarker of epithelial ovarian cancer is increased in type II tumors. Int J Cancer. 2013; 132 (11): 2597-2605
147. Escrevente C, Keller S, Altevogt P, et al. Interaction and uptake of exosomes by ovarian cancer cells. BMC Cancer. 2011; 11: 108
148. Escrevente C, Grammel N, Kandzia S, et al. Sialoglycoproteins and N-glycans from secreted exosomes of ovarian carcinoma cells. Plos One. 2013; 8 (10): E78631
149. Krishnamoorthy L, Bess JW Jr., Preston AB, et al. HIV-1 and microvesicles from T cells share a common glycome, arguing for a common origin. Nat Chem Biol. 2009; 5 (4): 244-250
150. Batista BS, Eng WS, Pilobello KT, et al. Identification of a conserved glycan signature for microvesicles. J Proteome Res. 2011; 10 (10): 4624-4633
151. Staubach S, Schadewaldt P, Wendel U, et al. Differential glycomics of epithelial membrane glycoproteins from urinary exovesicles reveals shifts toward complex-type N-glycosylation in classical galactosemia. J Proteome Res. 2012; 11 (2): 906-916
152. Shender VO, Pavlyukov MS, Ziganshin RH, et al. Proteome-metabolome profiling of ovarian cancer ascites reveals novel components involved in intercellular communication. Mol Cell Proteomics. 2014; 13 (12): 3558-3571
153. Bedard PL, Hansen AR, Ratain MJ, et al. Tumour heterogeneity in the clinic. Nature. 2013; 501 (7467): 355-364
154. Brock GC-RE, Hu L, Coticchia C, et al. Liquid biopsy for cancer screening, patient stratification and monitoring. Transl Cancer Res. 2015; 4 (3): 280-290
155. Kuhlmann JD, Rasch J, Wimberger P, et al. microRNA and the pathogenesis of ovarian cancer -A new horizon for molecular diagnostics and treatment? Clin Chem Lab Med. 2012; 50 (4): 601-615
156. Balaj L, Lessard R, Dai L, et al. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun. 2011; 2: 180
157. Kahlert C, Melo SA, Protopopov A, et al. Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J Biol Chem. 2014; 289 (7): 3869-3875
158. Huang X, Yuan T, Tschannen M, et al. Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics. 2013; 14: 319
159. Lunavat TR, Cheng L, Kim DK, et al. Small RNA deep sequencing discriminates subsets of extracellular vesicles released by melanoma cells-evidence of unique microRNA cargos. RNA Biol. 2015;12(8):810-823
160. Ji H, Chen M, Greening DW, et al. Deep sequencing of RNA from three different extracellular vesicle (EV) subtypes released from the human LIM1863 colon cancer cell line uncovers distinct miRNA-enrichment signatures. Plos One. 2014; 9 (10): E110314
161. Liao J, Liu R, Yin L, et al. Expression profiling of exosomal miRNAs derived from human esophageal cancer cells by Solexa high-throughput sequencing. Int J Mol Sci. 2014; 15 (9): 15530-15551
162. Noerholm M, Balaj L, Limperg T, et al. RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. BMC Cancer. 2012; 12: 22
163. Ogata-Kawata H, Izumiya M, Kurioka D, et al. Circulating exosomal microRNAs as biomarkers of colon cancer. Plos One. 2014; 9 (4): E92921
164. Cortez MA, Bueso-Ramos C, Ferdin J, et al. MicroRNAs in body fluids -The mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011; 8 (8): 467-477
165. Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007; 67 (18): 8699-8707
166. Bagnoli M, De Cecco L, Granata A, et al. Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients. Oncotarget. 2011; 2 (12): 1265-1278
167. Chevillet JR, Kang Q, Ruf IK, et al. Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proc Natl Acad Sci USA. 2014; 111 (41): 14888-14893
168. Rank A, Liebhardt S, Zwirner J, et al. Circulating microparticles in patients with benign and malignant ovarian tumors. Anticancer Res. 2012; 32 (5): 2009-2014
169. Cappellesso R, Tinazzi A, Giurici T, et al. Programmed cell death 4 and microRNA 21 inverse expression is maintained in cells and exosomes from ovarian serous carcinoma effusions. Cancer Cytopathol. 2014; 122 (9): 685-693
170. Zhou J, Gong G, Tan H, et al. Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma. Oncol Rep. 2015; 33 (6): 2915-2923
171. Zavesky L, Jandakova E, Turyna R, et al. Evaluation of cell-free urine microRNAs expression for the use in diagnosis of ovarian and endometrial cancers. A pilot study. Pathol Oncol Res. 2015; 21 (4): 1027-1035
172. Meng X, Muller V, Milde-Langosch K, et al. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. Oncotarget. 2016. Mar 2. doi: 10.18632/oncotarget.7850. [Epub ahead of print]
173. Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials-an ISEV position paper. J Extracell Vesicles. 2015; 4: 30087
174. Melo SA, Luecke LB, Kahlert C, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015; 523 (7559): 177-182
175. Jeong S, Park J, Pathania D, et al. Integrated magneto-electrochemical sensor for exosome analysis. ACS Nano. 2016; 10 (2): 1802-1809.